Evidence map›Paper›PMID 41236792›Full record

SynthesisTechnology in cancer research & treatment

Prognostic Impact of Body Mass index in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: An Updated Systematic Review and Meta-Analysis.

Zhe Wang, Mengxue Yang, Yanlin Zhao, Jiaxin Wang, Mingyang Tao, Jingjing Yang, Jingxian Mao, Huaijuan Guo, Guohui Zhu, Xuebing Yan

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhe WangTongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Mengxue YangDepartment of Oncology, Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui, China.ORCID 0009-0002-7724-6132
Yanlin ZhaoDepartment of Pharmacy, Suining People's Hospital, Affiliated Hospital of Xuzhou Medical University, Suining, Jiangsu, China.
Jiaxin WangDepartment of Oncology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China.ORCID 0009-0002-7724-6132
Mingyang TaoDepartment of Oncology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China.
Jingjing YangDepartment of Oncology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China.
Jingxian MaoDepartment of Oncology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China.
Huaijuan GuoDepartment of Oncology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China.ORCID 0000-0001-7672-0053
Guohui ZhuDepartment of Urology, Suining People's Hospital, Affiliated Hospital of Xuzhou Medical University, Suining, Jiangsu, China.
Xuebing YanJiangsu Provincial Innovation and Practice Base for Postdoctor, Suining People's Hospital, Yangzhou University, Xuzhou, Jiangsu, China.ORCID 0000-0001-9069-5907

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionBody mass index (BMI) is a common clinical parameter associated with cancer prognosis, but its association with survival outcomes in lung cancer patients receiving immune checkpoint inhibitors (ICIs) remains unclear. This study aimed to clarify the prognostic value of BMI in ICI-treated lung cancer patients.MethodsA systematic review and meta-analysis were conducted based on online databases including PubMed, Embase, Web of Science, Cochrane Library, and ClinicalTrials.gov up to December 1, 2024. Eligible studies included lung cancer patients treated with ICIs and reported hazard ratios (HRs) for overall survival (OS) and/or progression-free survival (PFS) stratified by BMI. Random-effects models were used to determine HRs with 95% confidence intervals (CIs).ResultsA total of 30 studies involving 5987 patients were included. High BMI was significantly associated with better OS (HR = 0.69, 95%CI = 0.60-0.80) and PFS (HR = 0.82, 95%CI = 0.72-0.93). The subgroup analysis showed improved survival outcomes particularly in patients with BMI ≥ 30 kg/m

Indexed as

Body Mass IndexImmune Checkpoint InhibitorsLung NeoplasmsHumansPrognosisTreatment OutcomeImmune Checkpoint Inhibitorsbody mass indeximmune checkpoint inhibitorslung cancerprognosis and biomarker

Identifiers

PMID41236792
PMCPMC12618815

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.